Latest Prostate-specific antigen Stories
Men deserve to know where they stand to have a fighting chance and with early detection, the survival rate for prostate cancer can be over 90 per cent TORONTO, Oct.
Task Force says harms of PSA screening outweigh the benefits OTTAWA, Oct.
NEW YORK, Oct.
Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept.
-- Free Or Low Cost Screenings Help To Diagnose Second Leading Cause of Death Among Men Which Can Be Easily Treated If Caught Early -- DENVER, Sept.
Key evaluation to inform the US Food and Drug Administration regulatory submission SYDNEY, Sept.
Proprietary genomic-based VPAC1 cancer biomarker to be co-developed worldwide? PARK CITY, Utah, Sept. 17, 2014 /PRNewswire/ -- NuView Life Sciences, Inc.
- A political dynamiter.